Clinical trial
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
NCT00203372 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00203372 |
|---|---|
| Title | Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) |
| Official title | A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab 7.5 and TAC, Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), Bevacizumab 15 and TAC, Placebo 15 and TAC |
| Enrollment | 6 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 12, 2015 |
| Countries | Canada, Ireland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: